Elevance Health, Inc.
ELV
$313.35
-0.86%
Elevance Health, Inc. is a leading health insurer in the United States, providing medical benefits through employer, individual, and government-sponsored plans to approximately 45 million members. The company distinguishes itself as the largest single provider of Blue Cross Blue Shield branded coverage, operating as a licensee in 14 states, and has expanded its reach in government programs like Medicaid and Medicare Advantage through strategic acquisitions. The current investor narrative is dominated by sector-wide regulatory dynamics, specifically the recent larger-than-expected 2027 Medicare Advantage payment increase announced by CMS, which has boosted revenue visibility and sentiment for Elevance and its peers, though this positive catalyst is set against a backdrop of ongoing margin pressures and medical cost trends that have weighed on recent quarterly results.…
ELV
Elevance Health, Inc.
$313.35
Investment Opinion: Should I buy ELV Today?
Rating: Hold. The core thesis is that ELV presents a high-risk, high-potential-reward opportunity where severe fundamental headwinds are counterbalanced by a deeply discounted valuation and bullish analyst sentiment, making it a speculative turnaround bet rather than a clear-cut buy.
The Hold rating is supported by four key data points: 1) A forward PE of 10.58x implies a significant earnings recovery is already priced in, leaving little margin for error. 2) Revenue growth, while positive at 9.47% YoY, is decelerating sequentially. 3) Profitability metrics are in sharp decline, with net margin at 1.10%. 4) The stock trades 29.7% below its 52-week high, reflecting these acknowledged risks, yet analyst targets (implied by high EPS estimate of $50.74) suggest substantial upside if recovery occurs.
The two biggest risks that could invalidate a potential upgrade are: 1) A continuation of the quarterly net margin decline below 1%, signaling no cost control. 2) Revenue growth decelerating below 5% YoY. This Hold would upgrade to a Buy on demonstrated sequential improvement in net margin (e.g., back above 2%) and would downgrade to a Sell on a sustained break below the $273.71 support level. Relative to its own history, the stock is undervalued, but relative to its near-term fundamentals, it appears fairly valued given the significant uncertainty.
Sign up to view all
ELV 12-Month Price Forecast
The outlook is bifurcated between a potential valuation-driven recovery and continued fundamental erosion. The neutral stance reflects the high uncertainty, with the probability-weighted outcome leaning towards a sluggish, range-bound stock (base case 50%). The recent CMS news is a positive, but it must translate into tangible margin improvement in the next 1-2 quarters. The stance would upgrade to bullish on clear evidence of margin stabilization (net margin >2% for two consecutive quarters) and downgrade to bearish on a breakdown below the $273 support level, which would signal a failed recovery attempt.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $407.36 and implied upside of +30.0% versus the current price.
Average Target
$407.36
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$251 - $407
Analyst target range
Analyst coverage for ELV appears limited in the provided dataset, with only 3 analysts cited for EPS and revenue estimates, which is unusually low for a company of this market cap and suggests the input data may be incomplete. The consensus sentiment, as evidenced by recent institutional ratings, is overwhelmingly bullish, with firms like Mizuho, JP Morgan, Wells Fargo, Barclays, and Guggenheim all maintaining Buy, Overweight, or Outperform ratings in early 2026, and Wolfe Research upgrading to Outperform in January. The average revenue estimate for the period is $229.5 billion, with a wide range from $221.8 billion to $247.2 billion, indicating some uncertainty in the top-line outlook. The high end of the EPS estimate range at $50.74 versus a low of $44.11 suggests analysts hold varying degrees of confidence in the earnings recovery trajectory, with the high target likely incorporating a more optimistic view on medical cost trends and the benefit from favorable Medicare payment updates.
Bulls vs Bears: ELV Investment Factors
The investment debate for Elevance Health is a classic clash between deep value and deteriorating fundamentals. The bull case is anchored in a historically cheap valuation (13.73x trailing PE), a supportive regulatory catalyst, and strong analyst conviction in a recovery. The bear case is overwhelmingly focused on the alarming, sequential collapse in profitability, with net margin falling from over 4% to just 1% in three quarters. Currently, the bearish evidence from the fundamental deterioration is stronger, as reflected in the stock's severe price decline. The single most important tension is whether the recent CMS payment news and management execution can stem the margin bleed and validate the analyst recovery thesis, or if medical cost trends prove more persistent, trapping the stock in a value trap scenario.
Bullish
- Deep Valuation Discount to History: ELV trades at a trailing PE of 13.73x, near the bottom of its historical range, which has seen multiples above 35x. This significant compression suggests the market has priced in a severe margin deterioration scenario, creating a potential value opportunity if profitability stabilizes.
- Positive Regulatory Catalyst for Revenue: The recent larger-than-expected 2027 Medicare Advantage payment increase from CMS boosts revenue visibility for Elevance's substantial government business. This positive sector-wide news has already contributed to a 7.50% one-month stock price rally, outperforming the SPY.
- Major institutions including JP Morgan, Wells Fargo, and Barclays maintain Buy or Overweight ratings, with Wolfe Research recently upgrading to Outperform. This consensus bullishness, anchored by an average EPS estimate of $46.13, suggests professional conviction in an earnings recovery.
- Solid Balance Sheet and Cash Flow: The company maintains a manageable debt-to-equity ratio of 0.76 and generated robust trailing twelve-month free cash flow of $3.17 billion. This financial strength provides a cushion to navigate current margin pressures and supports the dividend, which yields 1.97%.
Bearish
- Severe and Accelerating Profitability Collapse: Net income plummeted from $2.18 billion in Q1 2025 to just $547 million in Q4 2025, with net margin collapsing from 4.47% to 1.10%. This sequential deterioration in both gross and net margins is the core fundamental risk, indicating intense medical cost pressure.
- Technical Downtrend and Weak Price Action: The stock is down 28.61% over the past year and trades near 70% of its 52-week range, having recently tested lows near $273.71. Despite a recent bounce, the prevailing downtrend and a 39.33% max drawdown reflect deep-seated investor skepticism.
- Volatile and Declining Quarterly Cash Flow: Quarterly operating cash flow turned negative in Q4 2025 at just $84 million, a stark contrast to the strong TTM FCF. This volatility raises concerns about the sustainability of cash generation amidst rising medical claims payouts.
- Decelerating Revenue Growth Trajectory: While Q4 2025 revenue grew 9.47% YoY, it declined sequentially from Q3's $50.71 billion. This moderation in top-line expansion, coupled with margin pressure, creates a challenging environment for earnings growth.
ELV Technical Analysis
The prevailing price trend for ELV is a pronounced downtrend, with the stock down 28.61% over the past year and currently trading at approximately 70% of its 52-week range, based on a current price of $311.53 relative to a 52-week high of $443.29 and low of $273.71. This positioning near the lower end of its annual range suggests the stock is in a deep correction, presenting a potential value opportunity but also reflecting significant fundamental and sector headwinds that must be resolved for a sustained recovery. Recent momentum shows a stark divergence, with the stock up 7.50% over the past month, sharply contrasting with its 3-month decline of 16.44% and 6-month drop of 11.81%; this positive 1-month move, which notably outperformed the SPY's 0.46% gain, could signal an attempt at mean reversion or a relief rally following the severe sell-off, particularly in response to the recent CMS payment news. Key technical levels are clearly defined by the 52-week low of $273.71 as critical support and the 52-week high of $443.29 as major resistance; a sustained breakdown below support would signal a continuation of the bearish trend, while a breakout above resistance seems distant and would require a significant fundamental catalyst. The stock's beta of 0.50 indicates it is approximately 50% less volatile than the broader market, which is typical for a large-cap managed care company but noteworthy given its recent sharp price declines, suggesting the moves have been driven by idiosyncratic and sector-specific factors rather than broad market sentiment.
Beta
0.50
0.50x market volatility
Max Drawdown
-39.3%
Largest decline past year
52-Week Range
$274-$441
Price range past year
Annual Return
-29.0%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +7.4% | +4.9% |
| 3m | -16.0% | +0.6% |
| 6m | -10.0% | +5.1% |
| 1y | -29.0% | +28.8% |
| ytd | -11.5% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue growth has been positive but decelerating on a sequential quarterly basis; Q4 2025 revenue was $49.75 billion, representing a solid 9.47% year-over-year increase, however, this follows higher growth rates in prior quarters (Q3 revenue was $50.71 billion), indicating a potential moderation in top-line expansion. The Health Benefits Segment, at $41.84 billion, remains the dominant revenue driver, while the Carelon Services Segment contributed $18.66 billion, highlighting the company's dual focus on insurance and healthcare services. Profitability has come under significant pressure, with net income in Q4 2025 plummeting to $547 million from $1.19 billion in Q3 2025 and $2.18 billion in Q1 2025, and the net margin compressing to 1.10% from 2.34% the prior quarter; gross margin also declined sequentially to 23.48% in Q4 from 24.79% in Q3, reflecting rising medical costs and competitive pressures. The sharp quarterly decline in profitability, from a net margin of 4.47% in Q1 2025 to just over 1% in Q4, is a critical concern and the central focus of the current investment debate. The balance sheet remains solid with a manageable debt-to-equity ratio of 0.76 and a current ratio of 1.24, indicating sufficient liquidity, while trailing twelve-month free cash flow is a robust $3.17 billion. However, quarterly operating cash flow was volatile, turning negative in Q4 2025 at just $84 million, and the return on equity of 12.90%, while positive, has likely declined from higher levels earlier in the year given the profit compression, suggesting capital efficiency is facing headwinds.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. ELV currently trades at a trailing PE of 13.73x and a forward PE of 10.58x, based on analyst estimates; the forward multiple being lower than the trailing multiple implies the market expects earnings to recover from the depressed Q4 2025 level. Compared to sector averages (data not explicitly provided in the input, but typical for managed care), a trailing PE in the low-teens is generally in line or at a slight discount, suggesting the market has priced in the recent profitability challenges. The discount to its own historical valuation is stark; the current trailing PE of 13.73x is near the bottom of its recent historical range, which has seen multiples above 35x in late 2025 and consistently above 15x for much of 2023-2024. Trading near historical valuation lows indicates the market is pricing in a pessimistic scenario regarding margin recovery and growth sustainability, presenting a potential value opportunity if the company can demonstrate a rebound in profitability, but also reflecting genuine fundamental deterioration that must be addressed.
PE
13.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on the precipitous decline in profitability. The net margin compression from 4.47% to 1.10% over three quarters indicates the company is struggling to manage medical costs, which comprised a large portion of the $49.1 billion in Q4 costs. While the balance sheet is solid (D/E 0.76), the volatility in operating cash flow—turning negative in Q4—raises liquidity concerns if the margin pressure persists. The company's revenue, while diversified, is heavily exposed to government programs where pricing is regulated, limiting pricing power to offset cost inflation.
Market & Competitive Risks include the stock's valuation potentially remaining depressed despite its historical discount. The trailing PE of 13.73x, while low, may not expand if the sector continues to face scrutiny over medical cost ratios and pricing. Competitive intensity is high among managed care giants, pressuring membership growth and pricing. The stock's low beta (0.50) offers little defense against these idiosyncratic sector risks, as evidenced by its 28.6% decline during a strong market year.
Worst-Case Scenario involves a failure to stabilize medical costs in the coming quarters, leading to further earnings misses and a breach of the 52-week low of $273.71. This could trigger a wave of analyst downgrades from the currently bullish consensus, eroding the primary support for the stock. In this adverse scenario, a retest of the March 2026 lows near $280 and a break below could lead to a downside of approximately -12% from the current $311.53 price to the 52-week low, with potential for further declines if sentiment sours drastically, mirroring the stock's 39.33% maximum drawdown.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The accelerating collapse in profitability, with net income falling 75% from Q1 to Q4 2025. 2) Operational Risk: Inability to control medical costs, as evidenced by the gross margin decline from 27.7% to 23.5%. 3) Market Risk: The stock remains in a strong downtrend, down 28.6% over the past year, and could breach key support. 4) Sentiment Risk: The currently bullish analyst consensus could reverse sharply on another earnings miss, removing a key support pillar.
The 12-month forecast is highly scenario-dependent. The base case (50% probability) sees the stock trading between $320 and $380 as margin pressure stabilizes but recovery is slow. The bull case (30% probability) targets $400 to $443 on a successful margin recovery and valuation re-rating. The bear case (20% probability) warns of a drop to the $273 to $300 range if profitability worsens. The most likely outcome is the base case, which assumes the company muddles through without a decisive turnaround or further collapse.
ELV is deeply undervalued relative to its own history, trading at a trailing PE of 13.73x versus historical multiples that have been above 35x. However, this discount is justified by the severe deterioration in fundamentals, notably the net margin collapse to 1.10%. Compared to sector peers, its low-teens PE is likely in line or at a slight discount, suggesting the market is pricing in a challenged outlook. The valuation implies the market expects only a modest earnings recovery; a forward PE of 10.58x indicates skepticism about a return to prior peak profitability.
ELV is a high-risk, potentially high-reward stock that may be suitable for speculative value investors, but is not a clear-cut 'good buy' for all. The potential 28%+ upside to the 52-week high of $443 is compelling, but it is counterbalanced by a severe 12% downside risk to the 52-week low of $274 and ongoing fundamental deterioration. It could be a good buy for investors who believe the analyst consensus is correct and that the margin collapse has bottomed, and who are willing to tolerate significant volatility. For most investors, a 'Hold' and watch approach is more prudent until profitability stabilizes.
ELV is not suitable for short-term trading due to its low beta (0.50) and sector-specific news-driven volatility. It is best approached as a medium-to-long-term (2+ years) speculative turnaround play. The long-term thesis depends on the company proving it can sustainably improve profitability, which will take multiple quarters to confirm. The 1.97% dividend yield provides a modest income component for holders, but the primary driver will be capital appreciation from a successful operational turnaround, making patience a necessity.